CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

Guide for Primary Health Care Providers: Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
2005

List of Abbreviations

AFB
acid-fast bacilli

AIDS
acquired immune deficiency syndrome

ALT
alanine aminotransferase

APHL
American Public Health Laboratories

AST
aspartate aminotransferase

ATS
American Thoracic Society

BCG
bacille Calmette-Guérin

CDC
Centers for Disease Control and Prevention

DHP
delayed-type hypersensitivity

DOT
directly observed therapy

EMB
ethambutol

FDA
Food and Drug Administration

HAART
highly active antiretroviral therapies

HIV
human immunodeficiency virus

IFN-γ
interferon-gamma

INH
isoniazid

LTBI
latent TB infection

MDR TB
multidrug-resistant tuberculosis

MDR LTBI
multidrug-resistant latent TB infection

MMWR
Morbidity and Mortality Weekly Report

NNRTIs
nonnucleoside reverse transcriptase inhibitors

PI
protease inhibitors

PPD
purified protein derivative

PZA
pyrazinamide

QFT
QuantiFERON®-TB test and QuantiFERON®-TB Gold test

RIF
rifampin

TB
tuberculosis

TNF-α
tumor necrosis factor-alpha

TST
tuberculin skin test

USPHS
U.S. Public Health Service

WHO
World Health Organization

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333